Discover how to fully exploit the mixed leukocyte reaction assay for assessing immunotherapeutics on dendritic cell function and mediated immune response.
Discover our latest article, titled Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma.
We very much look forward to attending the @Society for Immunotherapy of Cancer Annual Meeting in Boston from November 8 to 12, and to showcasing our recent research works through our posters. Plan to stop by to talk of them and about your research programs.
Discover our latest paper, titled Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
Discover our latest publication, which helps predict the survival of cancer patients treated with immune checkpoint inhibitors.
Here is our latest publication, titled A novel gut-restricted small molecule TLR2 agonist enhances immune checkpoint inhibitor efficacy in a preclinical mouse fibrosarcoma tumor model.
Discover our main news for the first half of 2022! Hear about the great opportunity that is our partnership with Domain Therapeutics, new cutting-edge platforms for biomarker translational research as well as our newest featured publication!
Here is our latest publication, titled Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small cell lung cancer.
Ovarian cancer ascites are a remarkable opportunity to improve your translational research and therapeutic testing!
In this collaborative work, researchers from Institut Bergonié, Institut Gustave Roussy, and Explicyte, demonstrated that presence of APAP in plasma from cancer patients before they undergo immunotherapy was independently associated with a worse clinical outcome.
As Olink®-certified service Provider, Explicyte offers now high proteomic analysis capabilities for comprehensive protein biomarker discovery using Olink® Target technology.
The GeoMx Whole Transcriptome Atlas (WTA) empowers to explore biology accross a tissue. The human whole transcriptome (over 18,000 protein-coding human genes) is measured in each region of interest to uncover biological changes at specific locations of the tissue.
The GeoMx Whole Transcriptome Atlas delivers the maximum amount of sensitivity and confidence in each transcript through its unique probe architecture. The WTA profiles over 18,000 protein-coding human genes based on the human gene nomenclature committee (HUGO1) database cross-referenced with available mRNA sequences in the National Center for Biotechnology’s Information (NCBI) RefSeq database.
The WTA then allows to explore pathways across the whole transcriptome in defined regions of interest.
- Whole transcriptome coverage with probes specific to protein coding mRNA sequences
- Compatible with common sample types such as formalin-fixed paraffin embedded (FFPE) or fresh frozen (FF) tissue and across all human tissues types
- Superior sensitivity to detect 1000s of unique human genes in <50 μm regions
- Robust performance across sample types including FFPE with high concordance with RNA-seq and RNAscope™
- Map single cell RNA-seq populations to their tissue location
The GeoMx Whole Transcriptome Atlas delivers the maximum amount of sensitivity and confidence in each transcript through its unique probe architecture. The WTA profiles over 18,000 protein-coding human genes based on the human gene nomenclature committee (HUGO1) database cross-referenced with available mRNA sequences in the National Center for Biotechnology’s Information (NCBI) RefSeq database.
The WTA then allows to explore pathways across the whole transcriptome in defined regions of interest.